FRI0026 U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination

M Verhoeven,J Bijlsma,M Borm,M De Hair,X Teitsma,P Welsing,F Lafeber,A Pethö-Schramm,J Jacobs,J Van Laar

doi:10.1136/annrheumdis-2018-eular.3691

FRI0026 U-act-early trial 3 years follow-up. the longer effectiveness of treat-to-target strategies in early ra with tocilizumab, methotrexate, or their combination

M Verhoeven, J Bijlsma + Show 8 more

Open Access

https://doi.org/10.1136/annrheumdis-2018-eular.3691

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2018

Affiliation: University Medical Center Utrecht, Roche (Netherlands), Roche (Switzerland)

#Sustained Drug Free Remission #Sustained Remission + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThe U-Act-Early trial was a 2 year placebo controlled, double-blind randomised controlled trial in early (DMARD-naïve) RA patients treated to the target of sustained remission (SR), starting with tocilizumab (TCZ),...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.